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Background: Through a transcriptome microarray analysis, we have isolated Anterior gradient protein 2 (AGR2) as a
gene up-regulated in papillary thyroid carcinoma (PTC). AGR2 is a disulfide isomerase over-expressed in several
human carcinomas and recently linked to endoplasmic reticulum (ER) stress. Here, we analyzed the expression of
AGR2 in PTC and its functional role.
Methods: Expression of AGR2 was studied by immunohistochemistry and real time PCR in normal thyroids
and in PTC samples. The function of AGR2 was studied by knockdown in PTC cells and by ectopic expression
in non-transformed thyroid cells. The role of AGR2 in the ER stress was analyzed upon treatment of cells,
expressing or not AGR2, with Bortezomib and analyzing by Western blot the expression levels of GADD153.
Results: PTC over-expressed AGR2 at mRNA and protein levels. Knockdown of AGR2 in PTC cells induced
apoptosis and decreased migration and invasion. Ectopic expression of AGR2 in non-transformed human thyroid cells
increased migration and invasion and protected cells from ER stress induced by Bortezomib.
Conclusions: AGR2 is a novel marker of PTC and plays a role in thyroid cancer cell survival, migration, invasion and
protection from ER stress.
Keywords: Thyroid cancer, AGR2, Endoplasmic reticulum stress, Survival, Migration and invasionBackground
Thyroid carcinomas arising from thyroid follicular cells
include papillary thyroid carcinoma (PTC), follicular thy-
roid carcinoma as well as the less common anaplastic
thyroid carcinoma [1-3]. PTC is a well-differentiated,
slow growing and treatable tumor. The tumor is usually
removed by surgery and treated by iodine 131-radiation
therapy, however a few PTC carriers develop recurrences
and distant metastases [4,5].
To look for genes potentially involved in the neoplastic
transformation of the thyroid gland, we conducted a
transcriptome microarray screening [6]. Among the genes
highly up-regulated in PTC, we focused on Anterior* Correspondence: giuliana.salvatore@uniparthenope.it
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reproduction in any medium, provided the orgradient protein 2 (AGR2). AGR2, also known as hAG-2
or Gob-4, is the human orthologue of the Xenopus laevis
protein XAG-2. In the frog embryo XAG-2 induces ce-
ment gland differentiation [7,8]. Several studies have
shown a significant function for AGR2 in biological path-
ways including cell migration and transformation [9,10].
AGR2 protein is up-regulated in several human carcin-
omas, including breast, pancreatic, ovarian, lung and pros-
tate ones, and is associated with a metastatic phenotype
and poor prognosis [11-16].
AGR2 was found up-regulated in several published
PTC microarrays [17-21]. Delys and colleagues produced
a list of genes modulated in PTC, by comparing their
data sets with two independent PTC microarray data
sets, and AGR2 scored as one of the genes commonly
up-regulated in PTC [19].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cancer model systems, affects cell proliferation, invasion,
survival and metastasis [9,10].
Recently, AGR2 has been shown to have structural char-
acteristics of the protein disulfide isomerase (PDI) family,
including a carboxyl-terminal endoplasmic reticulum (ER)
retention signal (KTEL) and a single thioredoxin-like do-
main with a CXXS motif [22]. PDI proteins catalyze for-
mation, reduction, and isomerization of disulfide bonds,
thereby facilitating the maturation of proteins in the ER
and ensure correct folding and multimerization of pro-
teins [23,24].
During tumorigenesis, the high proliferation rate of
cancer cells requires increased ER protein folding, assem-
bly, and transport, a condition that can induce ER stress
[25,26]. Importantly, AGR2 knock out mice showed ele-
vated ER stress [27]. AGR2 expression is induced by ER
stress, and siRNA-mediated knockdown of AGR2 in-
creased ER stress response [27,28]. It has been shown that
AGR2 exists in monomer/dimer equilibrium and that
intermolecular salt bridges involving glutamic acid 60 or
cysteine 81 (in the thioredoxin domain of AGR2) stabilize
the dimer [29-31]. Importantly, it was demonstrated that
dimerization of AGR2 is crucial in mediating the ER stress
signaling pathway [29]. AGR2 localizes in the ER of nor-
mal intestinal epithelial cells and is essential for in vivo
production of mucus [32,33]. Indeed, AGR2 mediates pro-
cessing of the intestinal MUC2 through formation of
mixed disulfide bonds [33].
In this work, we analyzed the expression of AGR2 in
PTC and its functional role.
Results
AGR2 is up-regulated in human PTC samples
We measured AGR2 expression by immunohistochemis-
try with an anti-AGR2 monoclonal antibody in 64 samples
including 25 normal thyroid (NT) samples and 39 PTC
samples. Representative immunohistochemical staining is
shown in Figure 1A, and the entire dataset is reported in
Table 1. AGR2 was expressed at low levels in normal thy-
roid glands (Figure 1A, inset 1). In contrast, several PTC
samples (PTC classical variant: 23 out of 28 samples;
PTC follicular variant: 5 out of 11 samples) were strongly
positive for AGR2 expression, and positivity was confined
to tumor cells (Table 1 and Figure 1A, inset 2). No stain-
ing was observed in the absence of the primary antibody
(Figure 1A, inset 3). Normal colon mucosa was used as
positive control (Figure 1A, inset 4).
To determine whether up-regulation occurred also at
RNA level, we verified AGR2 expression levels in a DNA
array dataset of 15 normal human thyroid (NT) and 43
PTC samples. As shown in Figure 1B, PTC samples
showed significantly increased AGR2 levels compared to
normal thyroid tissues (P < 0.0001). These findings werefurther confirmed by quantitative RT-PCR analysis of an
independent set of PTC samples (Figure 1C).
Knockdown of AGR2 induces apoptosis of TPC-1 cells
We evaluated the expression level of AGR2 in the papil-
lary thyroid cancer cell line TPC-1 in comparison to
non-transformed thyroid cells Nthy-ori 3–1. As shown
in Figure 2A, AGR2 is over-expressed in TPC-1 cells.
We evaluated the effects of AGR2 ablation in TPC-1
cells by RNA interference. TPC-1 cells were transfected
with AGR2 siRNA or with scrambled siRNA, counted and
lysed at different time points. Forty-eight hours after
transfection TPC-1 cells transfected with scrambled
siRNA numbered 192 × 103, whereas those transfected
with AGR2 siRNA numbered 146 × 103 (P = 0.0492). Sev-
enty–two hours after transfection, TPC-1 cells transfected
with scrambled siRNA numbered 413 × 103, whereas
those transfected with AGR2 siRNA numbered 279 × 103
(P = 0.0045) (Figure 2B). Accordingly, the fraction of try-
pan blue excluding (viable) cells of TPC-1 transfected with
AGR2 siRNA, was reduced with respect to scrambled
control, at 48 and 72 hours post transfection (P < 0.0001)
(Figure 2C).
Knockdown of AGR2 reduces migration and invasion of
TPC-1 cells
We evaluated migration (by a wound-closure assay) and
invasion (by a Matrigel invasion assay) ability of AGR2
siRNA-transfected cells. A scraped wound was introduced
on a confluent monolayer of TPC-1 cells transfected with
AGR2 siRNA or scrambled siRNA. Figure 2D and E show
that TPC-1 transfected with the scrambled control effi-
ciently migrated into the wound; in contrast, cells trans-
fected with AGR2 siRNA had a reduced migrating ability
both at 12 and 24 hours (P < 0.0001). Moreover, cells
transfected with AGR2 siRNA showed a reduced ability to
invade Matrigel compared to control cells (P < 0.0001)
(Figure 2F and G). The efficiency of AGR2 knockdown at
the different time points examined is shown in Figure 2H.
Ectopic AGR2 promotes migration and invasion of
Nthy-ori 3–1 cells
We transfected the non-transformed thyroid cells, Nthy-
ori 3–1, with the empty vector (pcDNA), AGR2 wild type,
AGR2-carrying the cysteine 81 to serine mutation AGR2
(C→ S), or AGR2 carrying the glutamic acid 60 to alanine
mutation AGR2 (E→A) (Figure 3A). Wild type AGR2,
after treatment with disuccinimidyl suberate (DSS), is di-
meric (Additional file 1: Figure S1). The C81S mutation
targets the thioredoxin domain of AGR2 and impairs its
catalytic activity and dimer formation, while the E60A
mutation impairs AGR2 dimer formation [29-31]. Nthy-
ori 3–1 AGR2, AGR2 (C→ S), AGR2 (E→A) and
pcDNA cells showed comparable growth rates (Figure 3B).
Figure 1 AGR2 expression in human thyroid tissue samples. A) Representative images (at 200x magnification) of normal thyroid (NT) (inset 1),
papillary thyroid carcinoma (PTC) (inset 2), normal colon sample (inset 4) (used as positive control) stained with a mouse monoclonal anti-AGR2
antibody. PTC shows a strong immunoreactivity for AGR2, whereas NT is negative. Inset 3, shows a PTC sample incubated only with secondary
antibody as negative control. B) Expression of AGR2 in DNA array of 15 normal thyroid (NT) samples and 43 PTC. The box plot of AGR2 shows
a significant up-regulation of this gene in tumor tissues. C) Quantitative RT-PCR showing increased levels of AGR2 in PTC samples (n = 10) in
comparison to normal thyroid controls (n = 10). The level of AGR2 expression in each sample was measured by comparing its fluorescence
threshold with the average fluorescence threshold of the NT samples.
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layer and cell migration into the wound was monitored
after 12 hours. As shown in Figure 3C and D, migrationrate was larger in AGR2-transfected cells compared to con-
trol vector (pcDNA), AGR2 (C→ S) and AGR2 (E→A)
cells. Then we seeded AGR2, AGR2 (C→ S) and vector
Table 1 AGR2 expression in thyroid samples (n = 64)
Tissue* Number of
samples**
AGR2 (score***)
Negative Positive
0 1+ 2+ 3+
NT 25 4 21
PTC 28 (PTC CV) 1 2 2 23
11 (PTC FV) 2 1 3 5
*NT = normal thyroid; PTC = papillary thyroid carcinoma.
**PTC CV = papillary thyroid carcinoma, classical variant; PTC FV = papillary
thyroid carcinoma, follicular variant.
***0 = < 10% of positive cells; 1 = 10-50% of positive cells; 2 = 51-75% of
positive cells; 3 = 76-100% of positive cells.
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and evaluated their ability to invade Matrigel. AGR2 over-
expression increased the invasive ability of Nthy-ori 3–1
cells in comparison to vector control (P < 0.0001) and
AGR2 (C→ S) cells (P < 0.0001) (Figure 3E and F).
Ectopic AGR2 promotes cell migration and invasion of
TPC-1 cells
To confirm these findings, we over-expressed AGR2
in TPC-1 cells. Cells were transfected with AGR2,
AGR2 (C→ S), AGR2 (E→A) or with the empty vec-
tor (pcDNA). Mass populations were selected in G418
(Additional file 1: Figure S2A). Growth rates of TPC-1
AGR2, AGR2 (C→ S), AGR2 (E→A) and control (pcDNA)
cell lines were similar (Additional file 1: Figure S2B). We
studied cell migration using the wound closure assay. As
shown in Additional file 1: Figure S2C, migration rate was
larger in TPC-1 AGR2 cells compared to AGR2 (C→ S),
AGR2 (E→A) cells and to vector control (pcDNA) cells.
We next seeded TPC-1 AGR2, AGR2 (C→ S), and
pcDNA control cells into the top chamber of transwells
and evaluated their ability to invade Matrigel. AGR2 over-
expression increased TPC-1 invasiveness in comparison
to AGR2 (C→ S) cells and control vector (Additional
file 1: Figure S2D).
Nthy-ori 3–1 AGR2 cells have an increased disulfide
isomerase activity
AGR2 has been identified as a protein disulfide isomerase,
playing a role in the endoplasmic reticulum (ER) stress re-
sponse [22-33]. Protein disulfide isomerases catalyze the
formation (oxidation), breakage (reduction) and rearrange-
ment (isomerization) of disulfide bonds between cysteine
residues within proteins during their folding process.
To determine whether AGR2 had a disulfide isomer-
ase activity in thyroid cells we performed an insulin-
reduction assay. In this assay, insulin reduction catalyzed
by protein disulfide isomerases in the presence of dithio-
threitol (DTT) results in the aggregation of its β chains
that can be spectrophotometrically revealed at 650 nm
[34]. As shown in Figure 4A, Nthy-ori 3–1 AGR2 cellsshowed an increased rate of insulin reduction compared
to AGR2 (C→ S) or vector control cells.
To confirm these findings, we measured the levels of
oxidized (GSSG) and of reduced (GSH) glutathione in
Nthy-ori 3–1 AGR2, AGR2 (C→ S) and vector control
cells. As shown in Figure 4B and C, levels of GSSG and
GSH were increased in Nthy-ori 3–1 AGR2 cells com-
pared to AGR2 (C→ S) and to vector control cells. Fi-
nally, as shown in Figure 4D Nthy-ori 3–1 AGR2 cells
displayed a decreased level of H2O2 compared to vector
control and to AGR2 (C→ S) cells (P < 0.001).
AGR2 protects non-transformed thyroid Nthy-ori 3–1 cells
from endoplasmic reticulum stress
It was shown that AGR2 has a role in the endoplasmic
reticulum (ER) stress response [27-30]. Thus, we studied
the effects of ectopic AGR2 expression in the ER stress
pathway upon treatment with Bortezomib. Bortezomib is
a potent and selective inhibitor of the proteasome that
causes an accumulation of unfolded proteins in the ER
[35-37]. Nthy-ori 3–1 cells transfected with AGR2, AGR2
(C→ S), or vector (pcDNA) were treated for 24 hours
with 100 nM Bortezomib. After treatment, cells were
counted. As shown in Figure 5A, AGR2 protected Nthy-
ori 3–1 cells from reduced viability caused by Bortezomib
in comparison to AGR2 (C→ S) and to control (pcDNA)
cells.
Then, we determined by Western blot the expression
level of GADD153 (also named Chop), a well-characterized
biomarker of ER stress [37], in Nthy-ori 3–1 AGR2,
AGR2 (C→ S) or empty vector (pcDNA) cells treated
with Bortezomib (100 nM) for 24 hours. As shown in
Figure 5B, Nthy-ori 3–1 AGR2 cells presented a blunted
increase of GADD153 upon Bortezomib treatment
compared to pcDNA and to AGR2 (C→ S) cells. These
data suggest that ectopic AGR2 expression protects
non-transformed thyroid cells from ER stress induced
by Bortezomib.
Discussion
AGR2 is a protein disulfide isomerase that is over-
expressed in several human carcinomas and stimulates
cancer cell proliferation, survival, invasion, and metasta-
sis [9,10]. In the present study, we demonstrated that
AGR2 is over-expressed in PTC. Our data are in agree-
ment with thyroid carcinoma microarray screenings that
isolated AGR2 as a gene up-regulated in PTC [17-21].
We investigated the functional role of AGR2 using
gain and loss-of-function approaches. Knockdown of
AGR2 in PTC cells decreased cell survival, migration
and invasion. On the other hand, forced AGR2 expres-
sion in non-transformed thyroid Nthy-ori 3–1 cells, re-
sulted in increased cell migration and invasion and
protection from ER stress.
Figure 2 Effects of AGR2 knockdown on TPC-1 cell growth, migration and invasion. A) Expression levels of AGR2 in Nthy-ori 3–1 and TPC-1
cells. Cells were lysed and analyzed by Western blotting with the indicated antibodies. B) TPC-1 cells were transfected with AGR2 siRNA or with
scrambled siRNA and counted at different time points. Values represent the average of triplicate experiments ± standard deviations. C) TPC-1 cells
were transfected with AGR2 siRNA or with scrambled siRNA; after 48 and 72 hours cells were collected by trypsinization, stained for 10 minutes
with trypan-blue and counted in triplicate. The percentage of trypan blue excluding cells compared to cells transfected with scrambled siRNA is
reported ± standard deviations. D) TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA; after 48 hours a wound was introduced
and cell migration into the wound was monitored at 12 and 24 hours. E) Wound closure was measured by calculating pixel densities in the wound
area and expressed as percentage of wound closure of triplicate areas ± standard deviations. F) TPC-1 (1 × 105) cells were transfected with AGR2 siRNA
or with scrambled siRNA; 48 hours after transfection, cells were seeded in the upper chamber of transwells and incubated for 24 hours; the upper
surface of the filter was wiped clean and cells on the lower surface were stained, photographed and counted. This figure is representative of three
independent experiments. G) Invasive ability is expressed as number of invaded cells. Values represent the average of triplicate experiments ± standard
deviations. H) TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA. Cells were harvested at different time points and protein lysates
were subjected to immunoblotting with the indicated antibodies. Asterisks indicate P < 0.05 (*), P <0.01 (**) and P < 0.001 (***).
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the ER and their accumulation may constitute a form
of stress to the cell. Several signaling pathways, col-
lectively known as unfolded protein response (UPR),
have evolved to detect the accumulation of misfolded
proteins in the ER and activate a cellular response tomaintain homeostasis [25,26]. As a member of the
protein disulfide isomerase family, AGR2 aids protein
folding and assembly by catalyzing the formation, re-
duction, and isomerization of disulfide bonds, thereby
stabilizing intermediate conformations during protein
maturation in the ER.
Figure 3 Effects of AGR2 ectopic expression on Nthy-ori 3–1 cell growth, migration and invasion. A) Expression levels of AGR2, AGR2
(C→ S) and AGR2 (E→ A) in transfected Nthy-ori 3–1 cells: after G418 selection, cells were lysed and analyzed by Western blotting with the
indicated antibodies. B) Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S), AGR2 (E→ A) or empty vector (pcDNA) were plated and counted
at different time points. Values represent the average of triplicate experiments ± standard deviations. C) A wound was introduced on confluent
monolayer of Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S), AGR2 (E→ A) and vector control (pcDNA) and wound closure was
monitored at 12 hours time points. D) Wound closure was measured by calculating pixel densities in the wound area and expressed as
percentage of wound closure of triplicate areas ± standard deviations. E) Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S) or the empty
vector (pcDNA) were seeded in the upper chamber of transwells and incubated for 24 hours; the upper surface of the filter was wiped clean and
cells on the lower surface were stained and counted. F) Invasive ability was expressed as number of invaded cells. Values represent the average
of triplicate experiments ± standard deviations. Asterisks indicate P < 0.001 (***).
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acts as a disulfide isomerase in Nthy-ori 3–1 cells. By evalu-
ating the aggregation of insulin as a result of reduc-
tion of disulfide bonds catalyzed by protein disulfide
isomerase, we demonstrated that AGR2 over-expressing
cells have an increased disulfide isomerase activity com-
pared to control cells, an increased levels of GSSG and
GSH and a decreased level of H2O2.
Further, we showed that wild type AGR2 is dimeric in
transfected Nthy-ori 3–1 cells treated with DSS. Interest-
ingly, it was recently demonstrated that dimerization ofAGR2 attenuates ER stress-induced cell death through the
association with BiP/GRP78 [29-31].
Increased expression of the UPR components, includ-
ing GADD153 has been detected in breast, lung, gastric,
and esophageal carcinomas [38-40]. In this context, our
hypothesis is that AGR2 is up-regulated by PTC cells to
cope with the ER stress. Thus, as shown for other ER
resident proteins [25,26], increased AGR2 expression in
PTC could enhance ER folding capacity and allow cancer
cells to cope with increased protein production and se-
cretion [41,42].
Figure 5 Effects of Bortezomib in Nthy-ori 3–1 cells ectopically expressing AGR2. A) Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S)
or with the empty vector (pcDNA) were treated for 24 hours with Bortezomib 100 nM. After treatment, cells were collected by trypsinization and
counted in triplicate. The percentage of total cell number respect to untreated cells is reported ± standard deviations. B) Nthy-ori 3–1 cells
transfected with AGR2, AGR2 (C→ S) or with the empty vector (pcDNA) were treated for 24 hours with Bortezomib 100 nM. After treatment,
cells were lysed, and protein lysates were subjected to immunoblotting with the indicated antibodies. Asterisks indicate P < 0.001 (***).
Figure 4 Disulfide isomerase activity of AGR2 and intracellular redox state. A) The disulfide isomerase activity of AGR2 was assayed with
the insulin precipitation method. The absorbance at 650 nm was plotted against time (minutes). Only dithiothreitol was used as blank.
B-C) Levels of GSSG and GSH in Nthy-ori 3–1 AGR2, AGR2 (C→ S) and vector control cells were determined using GSH and GSSG assay
kit. Values represent the average of duplicate experiments ± standard deviations. D) Nthy-ori 3–1 AGR2, AGR2 (C→ S) and vector control
cells were incubated H2DCFDA (100 μM) and levels of H2O2 were measured as described in Methods. Asterisks indicate P < 0.001 (***).
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Here, we demonstrated that AGR2 plays a key role in thy-
roid cancer cell survival, migration, invasion and protec-
tion from ER stress. AGR2 may be one of the pro-survival
factors used by cancer cells to overcome stress due to ex-
cess protein production and to assist protein folding, deg-
radation or both. These findings suggest that AGR2 could
be exploited as a molecular marker of PTC.
Methods
Tissue samples
Tumor (n = 39) and normal (n = 25) thyroid tissue sam-
ples for immunohistochemical analysis were retrieved
from the Pathology Department of the Istituto Pascale,
Naples, Italy. In addition, RNA from frozen tissues of 10
PTC cases and 10 normal matched thyroid controls was
obtained from the Chernobyl Tissue Bank (http://www.
chernobyltissuebank.com) [43]. A set of 43 PTC and 15
normal thyroid tissues, also obtained from Chernobyl Tis-
sue Bank, was used in the DNA array study (HG-U133
Plus 2.0, Handkiewicz Junak et al., manuscript submitted
for publication) carried out in MSC Memorial Cancer
Center and Institute of Oncology, Gliwice, Poland. In
all cases, the respective Institutional review boards ap-
proved the study. The samples were classified according
to the diagnostic criteria required for the identification of
PTC [44].
Immunohistochemical staining
Sections of paraffin-embedded samples were stained
with hematoxylin and eosin for histological examination
[44]. For immunohistochemistry, 2 μm paraffin sections
were deparaffinized and placed in a solution of 0.3%
hydrogen peroxide in absolute methanol for 30 minutes
and then washed in phosphate buffered saline (PBS) be-
fore immunoperoxidase staining. The slides were then
incubated overnight at 4°C in a humidified chamber with
mouse monoclonal antibody against AGR2 (PO1, Abnova,
Taipei City, Taiwan) diluted 1:100 in PBS. The slides were
subsequently incubated with biotinylated goat anti-mouse
IgG for 20 minutes (Vectostain ABC kits, Vector Labora-
tories) and then with premixed reagent ABC (Vector) for
20 minutes. The immunostaining was performed by incu-
bating the slides in diaminobenzidine (DAB, DAKO) solu-
tion containing 0.06 mM DAB and 2 mM hydrogen
peroxide in 0.05% PBS, pH 7.6, for 5 minutes, and after
chromogen development, the slides were washed, dehy-
drated with alcohol and xylene and mounted with cover-
slips using a permanent mounting medium (Permount).
Micrographs were taken on Kodak Ektachrome film with
a Zeiss system. Negative controls were performed in each
case by incubating tissue slides with secondary antibody
only. The expression of AGR2 was categorized as positive
(staining of ≥10% of the tumor cells) or negative (stainingof < 10% of the tumor cells). The staining intensity was
further graded in: score 1 (10-50% of positive cells), score
2 (51-75% of positive cells) and score 3 (76-100% of posi-
tive cells). Score values were independently assigned by
two blinded investigators (G.C. and M.M.) and a consen-
sus was reached on all scores used for computation.
Cell cultures
Human papillary thyroid cancer cell line TPC-1 was ob-
tained from M. Nagao (Carcinogenesis Division, National
Cancer Center Research Institute, Tokyo, Japan) and iden-
tified based on the presence of the RET/PTC1 rearrange-
ment. TPC-1 cell line was grown Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) supplemented with
10% fetal bovine serum (FBS), L-glutamine and penicillin/
streptomycin (Invitrogen). Nthy-ori 3–1 cells are non-
transformed human thyrocytes immortalized by the Large
T of SV40 and were obtained from the European Tissue
Culture collection (Sigma Aldrich, St. Louis, MO, USA).
Nthy-ori 3–1 cell line was grown in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with
10% fetal bovine serum (FBS), L-glutamine and penicillin/
streptomycin (Invitrogen, Carlsbad, California, USA).
Reagents
Bortezomib was obtained from Millenium (Cambridge,
MA, USA). Human insulin, disuccinimidyl suberate
(DSS) and dithiothreitol (DTT) were from Sigma Aldrich
(St. Louis, MO, USA). Glutathione reduced and oxidized
assay kit was obtained from Bioassay Systems (Hayward,
CA, USA).
Cell viability
For cell viability determination, cells were collected by
trypsinization stained for 10 minutes with 0.4% trypan-
blue (Sigma Aldrich) according to manufacturer’s in-
structions, and counted in triplicate.
Chemoinvasion
Cell invasion was examined using a reconstituted extra-
cellular matrix (Matrigel, BD Biosciences, San Jose, CA).
The cell suspension (1 × 105 cells per well) was added to
the upper chamber of transwell cell culture chambers on
a prehydrated polycarbonate membrane filter of 8 μm
pore size (Costar, Cambridge, MA) coated with 35 μg of
Matrigel (BD Biosciences). The lower chamber was filled
with 10% medium. After incubation at 37°C, non-migrating
cells on the upper side of the filter were wiped-off. Invading
cells were mounted on glass slides using mounting medium
and stained with Hoechst (Sigma Aldrich). Cell migration
was quantified by counting the number of stained nuclei in
three individual fields in each transwell membrane, by
fluorescence microscopy, in duplicate.
Di Maro et al. Molecular Cancer 2014, 13:160 Page 9 of 11
http://www.molecular-cancer.com/content/13/1/160Wound closure assay
A wound was introduced on the confluent monolayer
cells using a micropipette tip. Photographs were taken
at 40 X magnification using phase-contrast microscopy
immediately after wound incision and at selected time-
points. Wound closure was measured by calculating
pixel densities in the wound area by Cella software
(Olympus Biosystem Gmb, Hamburg, Germany) and
expressed as percentage of wound closure of triplicate
areas ± SD.
RNA silencing
A pool of 4 small inhibitor duplex RNAs (ON-TARGETplus
siRNA SMARTpool) targeting human AGR2 (#L-0036
26-00), and a non-targeting pool (ON-TARGETplus Non-
Targeting Pool) control (#D 001810-10-20) were purchased
from Dharmacon RNAi Technologies (Dharmacon Inc.,
Chicago, IL, USA). Cells were grown under standard con-
ditions. TPC-1 cells were plated in 60-mm dishes in
complete medium without antibiotics and electroporated
using MicroPorator (MP-100, Digital Bio, Euroclone,
Milan, Italy) according to the manufacturer’s instructions.
Cells were harvested at different time points after trans-
fection, counted and analyzed for protein expression.
Protein studies
Immunoblotting was carried out according to standard
procedures. Anti-AGR2 (PO1) monoclonal antibody was
from Abnova (Taipei City, Taiwan); anti-GADD153 (B-3,
sc-7351) and anti-α-tubulin monoclonal antibody was
from Sigma-Aldrich. Secondary anti-mouse and anti-
rabbit antibodies coupled to horseradish peroxidase were
from Santa Cruz Biotechnology.
Generation of stable AGR2 transfectants
cDNA containing the complete coding sequence of hu-
man AGR2 was produced by reverse transcription of
RNA from HT29 colon adenocarcinoma cells (American
Type Culture Collection, Rockville, MD, USA) using the
following primers:
AGR2 Cl For: 5′-ATCCTCGAGCGATCATGGAGA
AAATTCCA-3′;
AGR2 Cl Rev: 5′-ATCGGATCCCAATTCAGTCTTC
AGCAA-3′ (annealing temperature: 60°C).
AGR2 cDNA was cloned into pcDNA3.1 (named
pcDNA) (Invitrogen) by using BamHI and XhoI restric-
tion enzymes and verified by sequencing.
Point mutations in AGR2 that changed the cysteine at
position 81 to serine (C→ S) and glutamic acid at pos-
ition 60 to alanine (E→A) were introduced in the
pcDNA-AGR2 plasmid by the Stratagene QuikChange
site-directed mutagenesis kit (Agilent Technologies, Inc.
Life Sciences and Chemical Analysis Group, Santa Clara,
CA, USA).The following oligonucleotides were used:
AGR2 C81S For: 5′- CATCACTTGGATGAGTCCCC
ACACAGTCAAGC-3′;
AGR2 C81S Rev: 5′-GCTTGACTGTGTGGGGACT
CATCCAAGTGATG-3′ (annealing temperature: 55°C).
AGR2 E60A For: 5′- CTGGACTCAGACATATGAA
GCAGCTCTATATAAATCCAAGAC-3′;
AGR2 E60A Rev: 5′-GTCTTGGATTTATATAGAGCT
GCTTCTTCATATGTGTCCAG-3′ (annealing temperature:
55°C).
The Nthy-ori 3–1 and the TPC-1 cells were transfected
with pcDNA-AGR2, AGR2 (C→ S), AGR2 (E→A) or the
empty vector (pcDNA) using the Lipofectamine Reagent
(Invitrogen) according to the instructions of the manufac-
turer. Two days later, G418 (Invitrogen) was added at con-
centration of 0.3 mg/ml (Nthy-ori 3–1) or of 1.2 mg/ml
(TPC-1). Several clones and mass populations of transfec-
tants were isolated, expanded and screened for AGR2 ex-
pression by Western blotting.
Chemical crosslinking
Nthy-ori 3–1 AGR2 transfected cells were treated with
1 mM disuccinimidyl suberate (DSS). Cells were har-
vested and washed 3 times with ice-cold PBS. The cross-
linked cells were incubated for 60 minutes with mild
shaking at room temperature, and then quenched by
quenching buffer (1 M Tris, pH 7.5) to a final concen-
tration of 10 mM for 15 min at room temperature to
stop the chemical reaction. The chemically cross-linked
cells were subjected to Western blotting analysis.
Evaluation of GSSG, GSH and H2O2 levels
To measure the oxidized glutathione (GSSG) and reduced
glutathione (GSH), the EnzyChrom™ GSH and GSSG Assay
Kit (EGTT-100) (Bioassay Systems, Hayward, CA, USA)
was used according to manufacturer’s instructions. Intracel-
lular hydrogen peroxide levels were determined using the
cell-permeable probe 2′,7′-dichlorodihydrofluorescein dia-
cetate (H2DCFDA) that upon cleavage of the acetate groups
by intracellular esterases and oxidation is converted to
2′,7′-dichlorofluorescein (DCF) (Invitrogen, Carlsbad, CA).
DCF is a highly fluorescent compound that can be detected
by fluorescence spectroscopy using excitation and emission
wavelength of 485 nm and 538 nm, respectively. Cells were
incubated with H2DCFDA (100 μM) in complete media for
1 hour at 37°C. After that, cells were washed twice in PBS
and fluorescence intensity was quantified by microplate
reader (Perkin-Elmer Envision 2103 multilabel reader).
Insulin reduction assay
The disulfide isomerase activity was measured by the re-
duction of disulfide bonds in human insulin in the pres-
ence of DTT, giving rise to the aggregation of its β chain,
a process that can be followed by turbidimetry [32]. The
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60 μl of insulin (10 mg/ml) to cell lysates in a buffer con-
taining 100 mM sodium EDTA pH7 and 100 mM sodium
phosphate pH 7 to give a final volume of 500 μl. The reac-
tion started with the addition of 2 mM DTT and was
followed kinetically by the increase of absorbance at
650 nm, due to insulin β chain precipitation. The absorb-
ance at 650 nm was plotted.
RNA extraction and expression studies
Total RNA was isolated with the RNeasy Kit (Qiagen,
Crawley, West Sussex, UK). The quality of the RNAs was
verified by the 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany); only samples with RNA integrity
number (RIN) value > 7 were used for further analysis.
One μg of RNA from each sample was reverse-transcribed
with the QuantiTect® Reverse Transcription (Qiagen).
Quantitative RT-PCR
Quantitative RT-PCR was applied to study AGR2 expres-
sion in PTC samples (n = 10) and normal thyroid control
(n = 10). RNA from each sample was reverse-transcribed
with the QuantiTect® Reverse Transcription (Qiagen). For
quantitative RT-PCR, we used the Human ProbeLibray™
system (Roche). AGR2 and RNA polymerase 2 primers se-
quences were:
AGR2 For: 5′-CTG GCC AGA GATACC ACA GTC-3′;
AGR2 Rev: 5′-AGT TGG TCA CCC CAA CCT C-3′;
RNA pol-For: 5′-GCGATGAGAACAAGATGCAA-3′;
RNA pol-Rev: 5′-CGCAGGAAGACATCATCATC-3′.
PCR reactions were performed in triplicate and fold
changes were calculated with the formula: 2-(sample 1 ΔCt -
sample 2 ΔCt), where ΔCt is the difference between the amp-
lification fluorescent thresholds of the mRNA of interest
and the mRNA of RNA polymerase 2 used as an internal
reference. Sample 1 represented each single PTC sample,
and sample 2 was the average of all (n = 10) normal thy-
roid samples.
Statistical analysis
Data are presented as mean ± standard deviations. Two-
tailed unpaired Student’s t test was used for all statistical
analysis. Mann–Whitney U test was used only for DNA
array data analysis. P < 0.05 was considered statistically
significant. Statistical analyses were carried out using the
Graph Pad InStat (version 3.1a, La Jolla, CA, USA).Additional file
Additional file 1: Figure S1. The chemical crosslinker DSS was added
to Nthy-ori 3-1 AGR2 cell suspension at final concentration of 1 mM.
Monomeric and dimeric AGR2 were detected by Western blotting with
AGR2 antibody. Tubulin levels were used for normalization. Figure S2.
Effects of AGR2 ectopic expression on TPC-1 cell growth, migration andinvasion. A) Expression levels of transfected AGR2, AGR2 (C→S) and AGR2
(E→A) in TPC-1 cells: after G418 selection, cells were lysed and blotted
with the indicated antibodies. Levels of exogenous AGR2 are shown.
B) TPC-1 cells transfected with AGR2, AGR2 (C→S), AGR2 (E→A) or empty
vector (pcDNA) were plated and counted at different time points. Values
represent the average of triplicate experiments ± standard deviations.
C) A wound was introduced on confluent monolayer of TPC-1 cells
transfected with AGR2, AGR2 (C→S), AGR2 (E→A) or vector control
(pcDNA) and wound closure was monitored at 24 hours time point.
D) TPC-1 cells transfected with AGR2, AGR2 (C→S) or the empty vector
(pcDNA) were seeded in the upper chamber of transwells and incubated
for 24 hours; the upper surface of the filter was wiped clean and cells on
the lower surface were stained.
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